Research programme: erythrocyte-encapsulated therapeutics - EryDelAlternative Names: Erythrocyte-encapsulated PAL - EryDel; Erythrocyte-encapsulated phenylalanine ammonia-lyase - EryDel; PAL erythrocyte-encapsulated - EryDel; Phenylalanine ammonia-lyase erythrocyte-encapsulated - EryDel
Latest Information Update: 06 Sep 2013
At a glance
- Originator EryDel
- Developer EryDel; University of Rome; University of Urbino
- Class Ammonia lyases
- Mechanism of Action Phenylalanine ammonia lyase replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 05 Sep 2013 Preclinical trials in Phenylketonuria in Italy (Intracoronary)